ABSTRACT BACKGROUND: The merits of ethnomedicine-led approach to identify and prioritize anticancer medicinal plants have been challenged as cancer is more likely to be poorly understood in traditional medicine practices. Nonetheless, it is also believed that useful data can be generated by combining ethnobotanical findings with available scientific studies. Thus, this study combined an ethnobtanical study with ligand based in silico screening to identify relevant medical plants and predict their anticancer potential based on their phytoconstiutents reported in scientific literatures.
INTRODUCTION
Cancer is a growing public health concern in many developing countries. For example, in Africa only, there were about 715,000 new cancer cases and 542,000 deaths in 2008. These figures are also expected to double in the next twenty years (1) .
Currently, the lack of access to modern cancer care coupled with other factors makes many cancer patients of the developing world dependent on traditional medicines (2) . Given the challenges of finding novel anticancer medications which are effective, safe, affordable and accessible, ethnobotanical and ethnopharmacological studies play important roles in identifying relevant medicinal plants that can be developed further.
Medicinal plants, which formed the basis of traditional medicine practices, have long been used by mankind for preventive and curative purposes (3, 4, 5) . Historically, ethnobotanical studies have resulted in drug discovery for numerous ailments including cancer (6, 7) . However, the extrapolation into western medicine has no always been direct like in the case of vincristine where therapeutic efficacy was remotely correlated with the indigenous use (8) . Apart from the general success of the ethnobotanical approach, its values and performance vary among different diseases. Its scientific importance has also been challenged in disease like cancer which are believed to be poorly characterized in traditional medicine practices (9) .
In spite of ethnobotanical study based claims of anticancer activity made by many, the National Cancer Institute (NCI) argues that it is unlikely for cancer to be established as a single disease entity in traditional medicine, particularly those internal organ neoplasms such as lung, colon, ovarian and prostate cancers (10) .
Such a challenge to the ethnomedicine based approach has been further complicated by the lack of theory based practice in many of the traditional medicine practices which makes the information on diseases and plants used less reliable. Hence, the ethnobotanincal data gathered will in general be inadequate to identify relevant medicinal plants for further expensive biological investigations (11) .
Still, ethnobotanical reports can provide reliable information in external tumors like skin cancer, external growths and swellings, tumors of the oral cavity, genital tumors despite the general issue of establishing cancer as a specific diseases in ethnomedicine (10) . Besides, their relevance in selecting plants for further investigation in the area of cancer can be enhanced by corresponding the findings with existing scientific literature (11) . Virtual screening methods, which are cost effective, fast and reliable, could be utilized to correlate findings from existing scientific studies and ethnobotanical surveys (12) . In retro, such methodological combination could also help understand the indigenously defined malady in terms of its links to cancer.
To this end, our study combined an ethnomedicne study with a ligand based in silico method. In doing so, the study aimed at providing a scientific basis for the existing traditional medicine practice in a complex disease like cancer and exploiting its potential for drug discovery and development. Accordingly, we studied the potential anticancer activity and drugability of phytochemicals found in plants identified based on an ethnobotanical survey. 
MATERIALS AND METHODS

Ethno-botanical part
Prediction of anticancer activity:
The anticancer activity was studied in silicousing a web server named Cancer Drug (CDRUG; http://bsb.kiz.ac.cn/CDRUG/).CDRUG uses relative frequency-weighted fingerprint and a hybrid score(HSCORE) to determine the similarity between compound of interest and those found within its dataset. It computespvalues for the similarity measures based on which anticancer activity is predicted as highly possible, possible and less possible. It has the ability to hit 65% positive results at a rate 0.05 false-positive (13) . Since it requires the Simplified Molecular Input Line Entry String (SMILES) of compounds to be investigated, PubChem(https://pubchem.ncbi.nlm.nih.gov/) and FoodDB(http://foodb.ca/) databases were used as sources of required entries. For a small number of compounds, line strings were also determined on Molinspiration Cheminformatics (www.molinspiration.com/). Ultimately, the SMILES and a single word name of the query compounds were fed in to CDRUG as inputs for the prediction analysis.
Evaluation of general and anticancer druglikeness:
The analysis to discriminate between drugable and non-drugable compounds was done only for those compounds predicted to have anticancer activity. Initially, they were evaluated against Lipinski's rule (14) . Next, GhoseViswanadhan-Wendoloski (GVW) drug like indices, which are based on the distribution of physicochemical properties and chemical components in Comprehensive Medicinal Chemistry (CMC) database, were used for the evaluation. Among the indices determined for general drug likeness and seven disease based drug classes, we used the physicochemical property based ranges (Preferred and Qualifying range) particularly set for antineoplastic drugability. We also determined the presence of relevant functional groups, as determined by Ghose et al (15) . All required physicochemical properties were determined online by Molinspiration (www.molinspiration.com/) and E-Dragon(http://www.vcclab.org) using SMILES and SDF files as required (16) . Finally, additional structure features of drug-likeness like aromatic rings and proportion of heavy atoms (R-value) were assessed (17) .
RESULTS
The initial ethnobotanical survey gathered information from twenty three participants, and we were able to identify eighteen different medicinal plants and five additives used in the preparation of medications for swellings in different parts of the body, locally called 'Gofla'. Another 35(13.21%) of the phytoconstituents were also predicted to have possible anticancer activity (P-value < 0.1). The mean logGI50 (the 50% growth inhibition concentration) values of the natural products with high possibility of antineoplastic activity ranged from -4.681 to -5.981, and the logGI50 of those constituents with possible bioactivity ranged from -5.000 to -7.914. Among the 34 compounds predicted to have high possibility of anticancer activity, 17(14 triterpenoids, 2 sesquterpenoid & 1 diterpenoid) were terpenes/terpenoids 9 (1 phenolic acid, 6 flavanoids, 1 phenylpropanoid &1 anthraquinone) were phenolic compounds, 5 (4 isoquinolones & 1 indole) were alkaloids, 2 were steroidal glycosides, and 1 was unclassified. Similarly, the possible group contained 17(4 monoterpenoids, 11 sesquiterpenoids & 2 diterpenoids) terpenes/terpenoids, 14(5 phenolic acids, 4 flavanoids, 2 stilbenoids & 1 phenylpropanoid) phenolic compound, 3(2 isoquinolone &1 indole) alkaloids, and 1 phenolic glycoside.
The drugability of the compounds was assessed by combing methods that are based on physicochemical properties and structural features. First, the general drug-likeness of predicted phytochemicals was evaluated using the Lipinski's rule of five. The rule states that most of orally absorbed drugs possess hydrogen bond donors (HBDs) ≤ 5, hydrogen bond acceptors (HBAs) ≤ 10, a molecular weight (MW) ≤ 500 Daltons and octanol/water partition coefficient (LogP) value of ≤ 5 (18) . The analysis of these molecular properties for the highly possible compounds have shown that 13(38.2%) and 18(52.9%) of the predicted active compounds have no or one violation, respectively. Among the possible compounds, 16(45.7%) have no violation and 16(45.7%) have only one violation. Thirty-one of the highly possible compounds and thirty of the possible compounds have molecular weight less than 500 Daltons. The LogP distribution showed that 16(47.1%) of the highly possible compounds and 24 (68.6%) of the possible compounds were under the limit set by the Lipinski rule. Over seventy-five percent of predicted compounds on both groups possessedfive HBDs or fewer. Over ninety percent of the predicted active compounds were with ten HBAs or fewer (Figure 1 Figure 2) . Analysis of rings and functional groups showed that 18(52.9%) of the highly possible natural products were with two or more of the structural features believed to be important for drug-likeness. A similar feature was also observed in 19(54.3%) of the possible phytochemicals. Heterocyclic rings (mainly aliphatic), alcohol and benzene were the most common groups in both sets of phytoconstituents. Functional groups like carboxyester, keto, aliphatic amine and hetero aromatic rings were also found in the predicted compounds. Nonetheless, no carboxamide group was found in any of the compounds. Besides, over seventy percent of the predicted phytochemicals were found to possess proportion of heavy atoms, i.e. a ratio of non-hydrocarbon atoms to the number of all non-hydrogen atoms (R-value), between 0.05 and 0.50 (Figure 2 ). 
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Traditional medicines, which are largely based on the use of plants as drugs, are estimated to be used approximately by 80% of the population in developing countries as primary healthcare sources (20) . This estimation may be higher for diseases like cancer where treatment options are usually inaccessible and/or unaffordable. Given this magnitude of use, it is in the public's health interest to identify these medicinal plants and generate scientific evidence on their efficacy. Hence, we conducted an ethnobotanical survey followed by a ligand based computational study to identify and evaluate their therapeutic value claimed in the traditional practice.
Medicinal plants have played a huge role in anticancer drug discovery. They contributed to the discovery of around 48% of all anticancer drugs between 1940 and 2002 (21) . Many of these plants were used in different traditional medicines for ages. Although the importance ethnobotanical directed drug discovery efforts have been challenged due to their limited impact in the last two decades and unsatisfactory performance when compared to random screening approach, such approaches still play a useful role in drug discovery programs (22) .We do believe that an in silico method imparts cost and time effectiveness given the limitations of the approach while harnessing its potential. Accordingly, a ligandbased in silico approach was used to identify phytochemicals as possible hits or me-too drugs in addition to scientifically evaluating the herbal medicines traditional use.
According to a study on traditional medicine database, CDRUG was able to identify 5278 compound out of which 75% were similar to approved anticancer drugs (Tanimoto coefficient ≥ 0.70, MACCS fingerprint), and the top 346 compounds it identified were identical to compounds with proven anticancer activity on 60 cell lines (23) . Given such performance of CDRUG, our finding can be taken as a preliminary evidence of anticancer activity by many of the medicinal plants used for treating 'Gofla'. Among the 13 species whose phytochemicals were analysed, 11(84.6%) contained one or more compounds predicted to possess high possibility of anticancer activity. One or more phytoconstituents predicted to have a moderate possibility for bioactivity were also found in 12 (92.3%) of medicinal plants. The use of these plants in combinations in the traditional medicine practice may also enhance their activities by increasing both the amount and type of the predicted anticancer compounds in the preparations. Species such as Punica granatum, Boswellia papyrifera, Viscum schimperi and Fagara usambarensis contained higher number of compounds predicted to have anticancer activity in both categories. Nonetheless, these species should not be considered as having superior anticancer activity over the rest since the number of phytochemicals analysed for each of species varies.
Drug discovery is a challenging, time consuming and costly process. In small molecule drug development, the initial emphasis is largely on efficacy which makes addressing the issue of drugability secondary. This practice often leads to high failure rates and development costs (17) . Hence, we also assessed the general and antineoplastic drugability of relevant phytochemicals in addition to a similarity based prediction of anticancer activity. The initial evaluation using Lipinski's rule of five determined that over ninety percent of the predicted compounds to be drug-like as they contained no or only oneviolation (24) .
Since the Lipinski rule serves little to discriminate between drugs and non-drugs other than predicting oral bioavailability, we used additional rules that not only test the general druglikness but also the antineoplastic drugability (24) . The physicochemical properties used by Ghoseet al, are classified into two sets of ranges. The first one is the preferred range (50%) defined as the range within the qualifying range occupied by approximately 50% of the antineoplastic drugs in CMC database. Compounds with ALogP 0.0-3.7, AMR 60-107, MW 258-388 andnA 30-55 belong to this range. The fact that we found no compound of interest, which meet all the 50% criteria, may indicate the lack of novel chemical entities in our finding as this range is considered an efficient way of searching for new drugs. The second one is the qualifying range which covers 80% of the drugs and provides the advantage of reducing the chance of missing anticancer drug-like compounds. Compounds with ALogP -1.5-4.7, AMR 43-128, MW 180-475 and nA 21-63 are included to this range (25) . Contrary to the preferred range, we found 25 chemicals meeting all the criteria of this range. This augments the result from CDRUG in proving the anticancer activity of the predicted phytochemicals.
Structural features are important criteria in the assessment of drug-likeness. The combined presence of certain structures like benzene ring, heterocyclic rings (both aliphatic and aromatic), keto, alcohol, aliphatic amine, carboxamide and carboxyester groups, may signal antineoplastic and other drug likenesses (15) . Many of the bioactive natural products determined in this study contained all these features, which may be considered as an indication of good drugability in addition to efficacy. Aromatic rings either alone or combined with non-aromatic rings are relevant for antineoplastic activity, structural features possessed by over half of the predicted compounds. In addition, over two-third of identified phytochemicals possessed proportion of heavy atoms (R-value) between 0.05-0.50, which is thought to indicate good antineoplastic druglikeness. However, the fact that only 3(4.3%) of the predicted compounds contained an amine (-NH 2 ) group, a functional group thought to be beneficial for anticancer activity, may undermine the prediction of being both efficacious and drugable (17) . Generally, the evaluation based on important structural features found at least half of the predicted compounds to have good anticancer drugability.
Our investigation of both anticancer efficacy and drugability, which combined a hybrid score based similarity measure, rule of five, GVWdrug-likeness indices and structural features criteria, have determined a number of possible antineoplastic phytochemicals. These compounds have the potential for further study as possible hits or me-too drug sources of cancer treatment. Given the distribution of these phytochemicals, there is also a potential for many of the medicinal plants to possess anticancer activity. As far as the traditional medicine practice is concerned, there is an in silico evidence to suggest anticancer efficacy of the traditional treatments. The efficacy of these treatments may be even higher due to the practice of combining the medicinal plants, which can increase both the amount and type of predicted anticancer compounds within preparations.
